Torrent Pharmaceuticals Ltd — Performance & Outlook

Company Overview Torrent Pharmaceuticals is a leading Indian pharma company with strong presence in chronic therapies, domestic branded formulations, and growing international businesses across the US, Brazil, and Germany. Financial Performance • Q4 FY25 revenue: ₹2,959 crore (+8% YoY), FY25 revenue: ₹11,516 crore (+7%). • Q4 PAT: ₹498 crore (+11% YoY), FY25 PAT: ₹1,911 crore (+15%). • Q4 EBITDA: ₹964 crore, margin 32.6%; FY25 EBITDA: ₹3,721 crore, margin 32.3%. • Gross margins steady at 75-76%, R&D spend ~5% of revenues. Q1 FY26 Update • Revenue: ₹3,178 crore (+11% YoY). • PAT: ₹548 crore (+20% YoY). • EBITDA: ₹1,032 crore, margin ~32.5%. • India revenue up 11%, driven by chronic therapies. International business also delivered growth. Strategic Developments • Declared final dividend of ₹6 per share for FY25. • Aman Mehta to take over as Managing Director from August 2025. • Acquiring controlling stake in JB Chemicals & Pharmaceuticals (~₹19,500 crore deal) to scale operations. Strengths • Strong domestic branded formulations business, particularly in chronic therapies. • Consistent operating margins above 30%. • Diversified presence across key international markets. • Growth through strategic acquisitions. Risks & Challenges • Regulatory risks including price control penalties. • Currency fluctuations impacting international revenue. • Execution and integration risk from large acquisitions. • Competitive pressures in generics and regulated markets. Analyst View Torrent Pharma is maintaining steady growth momentum with strong profitability and a focus on branded chronic therapies. The JB Chemicals acquisition offers significant expansion opportunities, though integration and regulatory risks should be monitored. Suitable for investors seeking stable earnings growth with moderate risk.